Partner Clyde Tinnen was quoted in a Reorg article, “Healthcare Mergers Dwindle Despite Increase in Sector Activity,” about an expected decline in industry deals for both health care providers and pharmaceutical companies in light of the coronavirus pandemic.
Tinnen said enforcement changes made by regulators so far in response to the spread of the coronavirus appear aimed at collaboration and conduct rather than M&A. For industry players contemplating uncertain territories, he said, “the agencies will be there to guide them on how much information can be shared without divulging prohibited competitive information such as pricing data.”
(Subscription required.)
People
Related News
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."
August 5, 2025
In the News
Aaron Maguregui on Health Data Sharing Plan – 'I would expect the FTC to be heavily involved'
Foley & Lardner LLP partner Aaron Maguregui addressed a new health care data sharing initiative announced by the federal government in the Bloomberg Law article, "Digital Data-Sharing Plan Tests Limits of Health Privacy Rules."